Browse

Pregabalin add-on therapy using a flexible, optimized dose schedule in refractory partial epilepsies: A double-blind, randomized, placebo-controlled, multicenter trial

DC Field Value Language
dc.contributor.authorLee, Byung In-
dc.contributor.authorYi, Sangdoe-
dc.contributor.authorHong, Seung Bong-
dc.contributor.authorKim, Myeong-Kyu-
dc.contributor.authorLee, Sang Kun-
dc.contributor.authorKim, Jae Moon-
dc.contributor.authorHeo, Kyoung-
dc.contributor.authorLeon, Teresa-
dc.contributor.authorLowe, Wing-
dc.contributor.authorSong, Hong Ki-
dc.contributor.authorShin, Dong-Jin-
dc.contributor.authorLee, Sang Ahm-
dc.date.accessioned2012-06-18T06:04:13Z-
dc.date.available2012-06-18T06:04:13Z-
dc.date.issued2009-03-
dc.identifier.citationEPILEPSIA; Vol.50 3; 464-474ko_KR
dc.identifier.issn0013-9580-
dc.identifier.urihttps://hdl.handle.net/10371/77126-
dc.description.abstractPurpose: To evaluate the efficacy and safety of pregabalin (PGB) as adjunctive therapy, using a flexible-dosing schedule in Korean patients with refractory partial-onset seizures. Methods: This randomized, double-blind (DB), placebo-controlled trial consists of a 6-week baseline, a 12-week DB treatment, and a 1-week taper phase. Patients having recurrent partial seizures (4 seizures during baseline phase) under adequate pharmacotherapy were recruited to be randomized to PGB or placebo (PLC) in a 2 to 1 ratio. Starting dose was 150 mg/day, increased every 2 weeks by 150-mg/day increments up to maximum dose of 600 mg/day. The primary efficacy parameter was response ratio (RRatio) for all partial seizures. Results: A total of 178 patients (119 in PGB, 59 in PLC) were assigned to the study. Median daily doses of PGB and PLC were 367 and 420 mg/day, respectively. RRatio least squares (LS) mean was) -35.8 in the PGB group and) -23.2 in the PLC group, with estimated difference in RRatios being) -12.6 [95% confidence interval (CI):) 22.7 to) -2.5, p = 0.015] in the intent-to-treat (ITT) population. Analysis of secondary efficacy measures showed a general trend favoring PGB over PLC. Seventy-seven patients (64.7%) in the PGB group and 18 patients (30.5%) in the PLC group developed adverse events (AEs) related to the study drug. Seven patients (5.9%) in the PGB group discontinued the study prematurely because of AEs. In the post hoc analysis, a significant weight gain (>= 7% of baseline body weight) was found in 24.8% of patients taking PGB, which was more frequent in patients with a lower body mass index (BMI <= 20). Discussion: PGB was effective and easily tolerable as add-on treatment in an Asian population with refractory partial-onset seizures.ko_KR
dc.language.isoenko_KR
dc.publisherWILEY-BLACKWELL PUBLISHING, INCko_KR
dc.subjectPregabalinko_KR
dc.subjectResponse ratioko_KR
dc.subjectFlexible-dosing scheduleko_KR
dc.subjectAdd-on therapyko_KR
dc.subjectTolerabilityko_KR
dc.titlePregabalin add-on therapy using a flexible, optimized dose schedule in refractory partial epilepsies: A double-blind, randomized, placebo-controlled, multicenter trialko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor이병인-
dc.contributor.AlternativeAuthor이상도-
dc.contributor.AlternativeAuthor홍승봉-
dc.contributor.AlternativeAuthor김명규-
dc.contributor.AlternativeAuthor이상암-
dc.contributor.AlternativeAuthor이상건-
dc.contributor.AlternativeAuthor신동진-
dc.contributor.AlternativeAuthor김재문-
dc.contributor.AlternativeAuthor송홍기-
dc.contributor.AlternativeAuthor허경-
dc.identifier.doi10.1111/j.1528-1167.2008.01954.x-
dc.citation.journaltitleEPILEPSIA-
dc.description.citedreferenceBEYDOUN A, 2008, EXPERT REV NEUROTHER, V8, P1013-
dc.description.citedreferenceTaylor CP, 2007, EPILEPSY RES, V73, P137, DOI 10.1016/j.eplepsyres.2006.09.008-
dc.description.citedreferenceElger CE, 2005, EPILEPSIA, V46, P1926-
dc.description.citedreferenceRyvlin P, 2005, EUR J NEUROL, V12, P12-
dc.description.citedreferenceBrodie MJ, 2005, EPILEPSIA, V46, P1407-
dc.description.citedreferenceZareba G, 2005, DRUGS TODAY, V41, P509, DOI 10.1358/dot.2005.41.8.910482-
dc.description.citedreferenceBeydoun A, 2005, NEUROLOGY, V64, P475-
dc.description.citedreferenceBen-Menachem E, 2004, EPILEPSIA, V45, P13-
dc.description.citedreferenceBrodie MJ, 2004, EPILEPSIA, V45, P19-
dc.description.citedreferenceArroyo S, 2004, EPILEPSIA, V45, P20-
dc.description.citedreferenceHUCKLE R, 2004, CURR OPIN INVEST DR, V5, P82-
dc.description.citedreferenceFehrenbacher JC, 2003, PAIN, V105, P133, DOI 10.1016/S0304-3959(03)00173-8-
dc.description.citedreferenceArikkath J, 2003, CURR OPIN NEUROBIOL, V13, P298, DOI 10.1016/S0959-4388(03)00066-7-
dc.description.citedreferenceFrench JA, 2003, NEUROLOGY, V60, P1631-
dc.description.citedreferenceLauria-Horner BA, 2003, EXPERT OPIN INV DRUG, V12, P663-
dc.description.citedreferenceBurneo JG, 2002, EPILEPSY BEHAV, V3, P532-
dc.description.citedreferenceDooley DJ, 2002, SYNAPSE, V45, P171, DOI 10.1002/syn.10094-
dc.description.citedreferenceBirbeck GL, 2002, EPILEPSIA, V43, P535-
dc.description.citedreferenceFink K, 2002, NEUROPHARMACOLOGY, V42, P229-
dc.description.citedreferenceBENMENACHEM E, 2002, ANTIEPILEPTIC DRUGS, P901-
dc.description.citedreferenceDooley DJ, 2000, J PHARMACOL EXP THER, V295, P1086-
dc.description.citedreferenceBockbrader HN, 2000, NEUROLOGY, V54, pA421-
dc.description.citedreferenceCramer JA, 1999, EPILEPSIA, V40, P590-
dc.description.citedreferenceWILLIAMSON J, 1997, EPILIPSIA, V38, P29-
dc.description.citedreferenceBANCAUD J, 1981, EPILEPSIA, V22, P489-
dc.description.tc8-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Dept. of Neurology (신경과학교실)Journal Papers (저널논문_신경과학교실)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse